Acetylcholinesterase Inhibition Assays for High-Throughput Screening

Plausible Action of N-(3,4-Dimethoxy-Phenyl)-6,7-Dimethoxyquinazoline-4-Amine (TKM01) as an Armor Against Alzheimer's Disease: In Silico and In Vivo Insights

Alzheimer's disease (AD) affects millions of people and has limited treatment options, thus making it a global health concern. Amyloid β (Aβ), a disrupted cholinergic system with high acetylcholinesterase (AChE), oxidative stress (OS), reduced antioxidants, and neuroinflammation are key factors influencing AD progression. Prior research has shown that AChE can interact with Aβ and increase its accumulation and neurotoxicity, so targeting AChEs and Aβ could be a potential therapeutic approach for AD treatment. It has been known that nonsteroidal anti-inflammatory drugs (NSAIDs) can inhibit Aβ accumulation. Previously, TKM01, a derivative of 4-anilinoquinazoline, has demonstrated inhibitory effects against GSK-3β-a regulator in AD progression. The current research included molecular docking studies of NSAIDs and TKM01 with Aβ and AChEs as targets. TKM01 exhibited a higher binding affinity with Aβ among all tested compounds. Molecular dynamic (MD) simulations confirmed the stability of the protein-TKM01 complexes. TKM01 also exhibited favorable drug-likeness properties, and no hepatoxicity was visualized in comparison with other compounds. Further, in vitro assay showed an inhibitory action of TKM01 (50-1200 µg/mL) on AChEs. In the in vivo studies on zebrafish larvae brains, we found that TKM01 (120 and 240 µg/mL) reduced the levels of AChEs and lipid peroxidation (LPO) and increased antioxidant superoxide dismutase (SOD) and catalase (CAT) in AlCl3(80 µM)-induced AD-like model. Additionally, TKM01 treatment was found to decrease pro-inflammatory cytokines TNF-α, IL-1β, and IL-6. The current study demonstrates that TKM01 can be used to treat AD. Nonetheless, experimental validation is needed to reveal the cellular, sub-cellular, and molecular mechanisms and possible implications at a clinical stage.

Per-and polyfluoroalkyl substances and disrupted sleep: mediating roles of proteins

Background

Per-and polyfluoroalkyl substances (PFAS) contamination may disrupt sleep through disrupted metabolic and immune functions. The study aims to investigate the association and potential mechanism between PFAS and sleep.

Methods

We included 136 young adults recruited between 2014-2018 and 76 were re-assessed between 2020-2022. Additional 8 participants only had complete data between 2020-2022. Plasma PFAS (PFOS, PFOA, PFHxS, PFHpS, PFPeS, PFNA, PFDA) were measured at both visits using liquid-chromatography high-resolution mass spectrometry. Plasma proteins were measured by Olink® Explore 384 Cardiometabolic and Inflammation Panel I. Sleep duration was self-reported at both visits along with follow-up sleep disturbance and sleep-related impairment using validated instruments. We utilized multiple linear regression to explore the association between individual PFAS (in tertile) and these sleep outcomes. PFAS associated with sleep outcomes were subjected to computational toxicology analysis using the Comparative Toxicogenomics Database and Toxicology in the 21st Century database to identify potential genetic links between them. Mediation analysis using proteomic data was then performed to confirm the findings from computational toxicology analysis.

Results

At baseline, one tertile increase in PFDA was associated with 0.39 (95 % CI: 0.05, 0.73) hours of shorter nightly sleep duration, and, at follow-up, PFHxS and PFOA were associated with 0.39 (95 % CI: 0.05, 0.72) and 0.32 (95 % CI: 0.01, 0.63) hours shorter sleep duration, respectively. One tertile increase in PFOS exposure was associated with a 2.99-point increase in sleep disturbance scores (95 % CI: 0.67, 5.31) and a 3.35-point increase in sleep-related impairment scores (95 % CI: 0.51, 6.20). Computational toxicology and mediation analyses identified potential mediating roles for several proteins in the PFAS-sleep associations, including 11-beta-dehydrogenase isozyme 1 (HSD11B1), cathepsin B (CTSB) and several immune system-related proteins.

Conclusion

Future large scale epidemiological and mechanistic studies should confirm our findings and test effect measure modification of the associations by age.

Effects of dissolved organic matter on the environmental behavior and toxicity of metal nanomaterials: A review

Metal nanomaterials (MNMs) have been released into the environment during their usage in various products, and their environmental behaviors directly impact their toxicity. Numerous environmental factors potentially affect the behaviors and toxicity of MNMs with dissolved organic matter (DOM) playing the most essential role. Abundant facts showing contradictory results about the effects of DOM on MNMs, herein the occurrence of DOM on the environmental process change of MNMs such as dissolution, dispersion, aggregation, and surface transformation were summarized. We also reviewed the effects of MNMs on organisms and their mechanisms in the environment such as acute toxicity, oxidative stress, oxidative damage, growth inhibition, photosynthesis, reproductive toxicity, and malformation. The presence of DOM had the potential to reduce or enhance the toxicity of MNMs by altering the reactive oxygen species (ROS) generation, dissolution, stability, and electrostatic repulsion of MNMs. Furthermore, we summarized the factors that affected different toxicity including specific organisms, DOM concentration, DOM types, light conditions, detection time, and production methods of MNMs. However, the more detailed mechanism of interaction between DOM and MNMs needs further investigation.

β-cyclocitral, a novel AChE inhibitor, contributes to the defense of Microcystis aeruginosa against Daphnia grazing

β-cyclocitral is one of the major compounds in cyanobacterial volatile organic compound (VOCs) and can poison other aquatic organisms. To investigate the effect of β-cyclocitral on cyanobacterial-grazer interactions, Daphnia sinensis was fed Microcystis aeruginosa and exposed to β-cyclocitral. Our present study demonstrated that M. aeruginosa could significantly inhibit D. sinensis grazing. And the grazing inhibition by Microcystis aeruginosa results from the suppression of feeding rate, heart rate, thoracic limb activity and swimming speed of D. sinensis. In addition, M. aeruginosa could also induce intestinal peristalsis and emptying in D. sinensis. Interestingly, our present study found that the exposure to β-cyclocitral could mimic a range of phenotypes induced by M. aeruginosa in D. sinensis. These results suggested that M. aeruginosa could release β-cyclocitral to inhibit Daphnia grazing. To further examine the toxic mechanism of β-cyclocitral in Daphnia, several in vivo and in vitro experiments displayed that β-cyclocitral was a novel inhibitor of acetylcholinesterase (AChE). It could induce the accumulation of acetylcholine (ACh) by inhibiting AchE activity in D. sinensis. High level of endogenous Ach could inhibit feeding rate and induce intestinal peristalsis and emptying in D. sinensis.

High-Throughput Screening to Advance In Vitro Toxicology: Accomplishments, Challenges, and Future Directions

Traditionally, chemical toxicity is determined by in vivo animal studies, which are low throughput, expensive, and sometimes fail to predict compound toxicity in humans. Due to the increasing number of chemicals in use and the high rate of drug candidate failure due to toxicity, it is imperative to develop in vitro, high-throughput screening methods to determine toxicity. The Tox21 program, a unique research consortium of federal public health agencies, was established to address and identify toxicity concerns in a high-throughput, concentration-responsive manner using a battery of in vitro assays. In this article, we review the advancements in high-throughput robotic screening methodology and informatics processes to enable the generation of toxicological data, and their impact on the field; further, we discuss the future of assessing environmental toxicity utilizing efficient and scalable methods that better represent the corresponding biological and toxicodynamic processes in humans.

Single and joint toxicity of azoxystrobin and cyproconazole to Prochilodus lineatus: Bioconcentration and biochemical responses

Fungicides are widely used across the world to protect crops and their presence in freshwater systems is increasing. However, the evaluation of their potential impacts on non-target organisms is in the minority of studies related to pesticides. In the current research, the single and joint toxicity of azoxystrobin (AZX) and cyproconazole (CYP) was investigated in juvenile fish Prochilodus lineatus. In particular, we evaluated bioconcentration and biochemical responses following a short-term exposure to environmentally relevant concentrations of the fungicides (alone and in mixture). We also determined interactions between the biological responses when the two compounds were used in mixture. Our results demonstrate that AZX and CYP pose a risk to native freshwater fish by causing deleterious effects. Both compounds, alone and in mixture, bioaccumulated in P. lineatus and triggered neurotoxicity and changes in oxidative stress biomarkers in several organs. Moreover, muscle was a target tissue for these fungicides and a synergistic interaction was observed for the mixture. Due to the lack of studies in fish assessing the effects following exposure to AZX-CYP mixtures and considering a realistic exposure situation in agriculture-impacted water bodies, these findings provide new and relevant information for future studies.

Neurotoxicity and the potential molecular mechanisms of mono-2-ethylhexyl phthalic acid (MEHP) in zebrafish

Mono-2-ethylhexyl phthalic acid (MEHP) is the most toxic metabolite of plasticizer di-2-ethylhexyl phthalic acid (DEHP), and there is limited information available on the effects of MEHP on neurotoxicity. This study aims to examine the neurotoxicity of MEHP and preliminarily explore its potential molecular mechanisms. We found that MEHP impeded the growth of zebrafish embryos and the neurodevelopmental-related gene expression at environmentally relevant concentrations. MEHP exposure also induces oxidative stress response and brain cell apoptosis accompanied by a decrease in acetylcholinesterase (AChE) activity in zebrafish larvae. RNA-Seq and bioinformatics analysis showed that MEHP treatment altered the nervous system, neurogenic diseases, and visual perception pathways. The locomotor activity in dark-to-light cycles and phototaxis test confirmed the abnormal neural behavior of zebrafish larvae. Besides, the immune system has produced a large number of differentially expressed genes related to neural regulation. Inflammatory factor IL1β and IL-17 signaling pathways highly respond to MEHP, indicating that inflammation caused by immune system imbalance is a potential mechanism of MEHP-induced neurotoxicity. This study expands the understanding of the toxicity and molecular mechanisms of MEHP, providing a new perspective for in-depth neurotoxicity exploration of similar compounds.

Smartphone-assisted detection of monocrotophos pesticide using a portable nano-enabled chromagrid-lightbox system towards point-of-care application

With the aim of monocrotophos pesticides detection in environmental and food samples at point-of-care (PoC) application, this research, for the first time, explores silica alcogel as an immobilization matrix to support the development of in-house customized nano-enabled "chromagrid-lighbox" as a sensing system. This system is fabricated using laboratory waste materials and demonstrates the detection of highly hazardous monocrotophos pesticide using a smartphone. Nano-enabled chromagrid is a chip-like assembly filled with silica alcogel -a nanomaterial (hence the name "nano-enabled" chromagrid), and "chromogenic reagents" which is required for the enzymatic detection of monocrotophos. Lightbox is the imaging station fabricated to provide constant lighting conditions to the chromagrid to capture accurate colorimetric data. The silica alcogel used in this system was synthesized from Tetraethyl orthosilicate (TEOS) via a sol-gel method and characterized using advanced analytical techniques. Further, three chromagrid assays were developed for the optical detection of monocrotophos with a low detection limit (LOD) at 0.421 ng ml^-1 (by α-NAc chromagrid assay), 0.493 ng ml^-1 (by DTNB chromagrid assay) and 0.811 ng ml^-1 (by IDA chromagrid assay). The developed novel PoC chromagrid-lightbox system is capable of on-site detection of monocrotophos in environmental as well as food samples. This system is able to be manufacture prudently using recyclable waste plastic. Overall, such developed eco-friendly PoC testing system will surely manage rapid detection of monocrotophos pesticide needed for environmental and sustainable agricultural management.

Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer's disease: relevance for precision medicine in neurodegenerative diseases

Acetylcholinesterase inhibitors (ChEI) are the global standard of care for the symptomatic treatment of Alzheimer's disease (AD) and show significant positive effects in neurodegenerative diseases with cognitive and behavioral symptoms. Although experimental and large-scale clinical evidence indicates the potential long-term efficacy of ChEI, primary outcomes are generally heterogeneous across outpatient clinics and regional healthcare systems. Sub-optimal dosing or slow tapering, heterogeneous guidelines about the timing for therapy initiation (prodromal versus dementia stages), healthcare providers' ambivalence to treatment, lack of disease awareness, delayed medical consultation, prescription of ChEI in non-AD cognitive disorders, contribute to the negative outcomes. We present an evidence-based overview of determinants, spanning genetic, molecular, and large-scale networks, involved in the response to ChEI in patients with AD and other neurodegenerative diseases. A comprehensive understanding of cerebral and retinal cholinergic system dysfunctions along with ChEI response predictors in AD is crucial since disease-modifying therapies will frequently be prescribed in combination with ChEI. Therapeutic algorithms tailored to genetic, biological, clinical (endo)phenotypes, and disease stages will help leverage inter-drug synergy and attain optimal combined response outcomes, in line with the precision medicine model.